Early effects of contemporary breast radiation on health-related quality of life - predictors of radiotherapy-related fatigue.
Randi J Reidunsdatter, Toril Rannestad, Jomar Frengen...
https://pubmed.ncbi.nlm.nih.gov/21871005/Actively Recruiting
Led by St. Olavs Hospital · Updated on 2026-06-04
1600
Participants Needed
2
Research Sites
365 weeks
Total Duration
Breast cancer is the most common cancer diagnosed in women in Europe, representing 29% of cases, with a 5-year survival rate around 90%. Treatment often includes surgery, radiotherapy RT, anthracyclines, aromatase inhibitors, and trastuzumab Herceptin, which have improved survival. However, RT can lead to various cardiovascular diseases, a leading cause of non-cancer death among these patients. New RT techniques have reduced heart radiation exposure, but their impact on cardiovascular risks is not yet known. This observational study follows two groups of breast cancer patients one treated with conventional RT between 2007 and 2012, and another treated with laser-assisted breath-controlled RT between 2015 and 2017. Both groups may have also received anthracyclines andor trastuzumab. The study includes age-matched female controls from the general population to compare cardiovascular outcomes over 15 years. Participants will be monitored for the incidence and prevalence of cardiovascular diseases at 8 and 15 years after RT. Researchers will use cardiac magnetic resonance imaging, coronary fractional flow reserve, ECG, and biomarkers to detect acute heart toxicity and assess its ability to predict later cardiovascular problems. Traditional risk factors like age, hypertension, cholesterol, smoking, and physical activity before RT will also be evaluated throughout the study.
CONDITIONS
Acute and Long-term Cardiovascular Toxicity After Modern Radiotherapy for Breast Cancer
T
torgeir wethal, md phd
J
Jo-Åsmund Lund, md phd
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
St. Olavs Hospital
Lead Sponsor
Norwegian University of Science and Technology
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 15 years
Participants are followed for the development of cardiovascular disease after receiving different types of radiotherapy or as controls.
Periodic visits depending on cohort assignment
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Randi J Reidunsdatter, Toril Rannestad, Jomar Frengen...
https://pubmed.ncbi.nlm.nih.gov/21871005/St. Olavs Hospital
Lead Sponsor
Norwegian University of Science and Technology
Collaborating Sponsor